CureVac Appoints Stefan Mueller, Ph.D., as Vice President Preclinical
February 04, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Feb. 04, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today the...
CureVac Appoints Dimitris Voliotis, M.D., Dr. med., as Chief Development Officer
January 28, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Jan. 28, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today the...
CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants Against RSV
January 08, 2019 07:00 ET
|
CureVac AG
Important New Patent to Allow CureVac to Develop Vaccine Candidate for Neglected Respiratory Condition TÜBINGEN, Germany and BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully...
CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference
November 21, 2018 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Nov. 21, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan...
University of Tübingen Names CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, Honorary Senator
November 07, 2018 16:30 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, congratulates CureVac...